OS no-show for afatinib in PhIII head and neck trial
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim has reported data from a Phase III trial with afatinib (Gilotrif/Giotrif) that met its primary endpoint of significantly delaying tumor growth versus chemotherapy in patients with recurrent and/or metastatic (R/M) head and neck squamous cell cancer after failure of previous therapy. However, some observers have raised concerns over the failure of the trial to demonstrate overall survival benefit.